TABLE 2.

CXCL13 levels of study groups as measured by ELISA and LFA

Study group	n	Borrelia AI	CSF pleocytosis >5 cells/μl	CSF CXCL13 concna (range)		No. of CXCL13-positive patientsb (% of total)
				ELISA (pg/ml)	LFA (AV)	ELISA	LFA
Definite LNB (total)	34	Positive	Yes	1409 (91.4–39,370)	223.5 (1–427)	34 (100)	31 (91)
Possible LNB	5	Negative	Yes	4.6 (4.5–277.7)	0 (0–19)	2 (40)	0 (0)
	3	NDc	Yes	53.5 (7.9–106)	1 (0–30)	1 (33)	1(33)
	2	Positive	No	9.65 (4.5–14.8)	0 (0–0)	0 (0)	0 (0)
Total	10			11.35 (4.5–277.7)	0 (0–30)	3 (30)	1 (10)
Non-LNBd
Bacterial meningitis	8	Negative	6 yes, 2 ND	27.15 (4.5–14,645)	8 (0–373)	3 (38)	3 (38)
VZV encephalitis	10	Negative	9 yes, 1 no	31.5 (4.5– 350.6)	0 (0–20)	3 (30)	0 (0)
Multiple sclerosis	7	Negative	6 yes, 1 no	8.9 (4.5–107)	0 (0–2)	1 (14)	0 (0)
HSV encephalitis	4	Negative	3 yes, 1 ND	33.1 (19.2–47.3)	0 (0–3)	0 (0)	0 (0)
EV encephalitis	4	Negative	4 yes	27 (8.9– 58.5)	0 (0–1)	0 (0)	0 (0)
TBEV encephalitis	12	Negative	11 yes, 1 ND	8.15 (4.5–32.5)	0 (0–3)	0 (0)	0 (0)
Malignant melanoma	1	Negative	Yes	31.1	0	0 (0)	0 (0)
Total	46	Negative	40 yes, 2 no, 4 ND	20.7 (4.5–14,645)	0 (0–373)	7 (15)	3 (7)

^aData are presented as medians.

^bOptimized cutoff values (78.6 pg/ml for ELISA and AV of 22.5 for LFA) were used for classification.

^cND, not determined.

^dEV, enterovirus; TBEV, tick-borne encephalitis virus; VZV, varicella-zoster virus; HSV, herpes simplex virus.